UBS Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

UBS Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,000	Closed	-$62.4K	–	10492
2025 Q4	$62.4K	Hold	8,000	–	–	﹤0.01%	7120
2025 Q3	$60.7K	Hold	8,000	–	–	﹤0.01%	7427
2025 Q2	$71.7K	Hold	8,000	–	–	﹤0.01%	7495
2025 Q1	$60K	Hold	8,000	–	–	﹤0.01%	7440
2024 Q4	$60.2K	Hold	8,000	–	–	﹤0.01%	7182
2024 Q3	$60.8K	Hold	8,000	–	–	﹤0.01%	6689
2024 Q2	$49.4K	Buy	+8,000	New	+$44.1K	﹤0.01%	6697
2023 Q3	–	Sell	-26,800	Closed	-$189K	–	9456
2023 Q2	$189K	Hold	26,800	–	–	﹤0.01%	5519
2023 Q1	$224K	Hold	26,800	–	–	﹤0.01%	5300
2022 Q4	$308K	Hold	26,800	–	–	﹤0.01%	5101
2022 Q3	$338K	Buy	+26,800	New	+$345K	﹤0.01%	4678

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

UBS Group's BCRX Position: Q1 2026 in Review

UBS Group reduced its BioCryst Pharmaceuticals (BCRX) stake by 6.1% in Q1 2026, selling an estimated $2.48M and leaving 4,943,994 shares worth $47.1M. The position accounts for 0.01% of the portfolio, ranked #1706.

UBS Group first reported a position in BCRX in Q4 2014 and has held it in 46 quarters since. The position peaked at $50.3M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

UBS Group held 4,943,994 shares of BioCryst Pharmaceuticals worth $47.1M as of Q1 2026.
UBS Group sold 319,920 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $2.48M.
BioCryst Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q1 2026, its #1706 holding.
UBS Group first reported a position in BioCryst Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
UBS Group's BioCryst Pharmaceuticals position peaked at $50.3M in Q2 2025.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.